Adaptive Biotechnologies Corp vs iShares MSCI Canada (TSX) — how do they compare? Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.05B), while iShares MSCI Canada (TSX) trades at $61.51. Which is the better fit depends on your goals.
| ADPT | EWC | |
|---|---|---|
Market Cap | $4.05B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $25.45 | $61.51 |
52-Week Low | $12.30 | $47.00 |
Enterprise Value | $4.12B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
EWC, the iShares MSCI Canada ETF, trades at $61.30, up 0.99% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The fund faces headwinds from renewed U.S.-Canada trade tensions, including 50% tariffs announced in July 2026, though bullish analyst views highlight resilience due to energy and potash exclusions. Key financial ratios are unavailable in the provided data.
Outlook is mixed: technical strength supports near-term gains, but trade policy risks and overbought conditions warrant caution. Investment appeal hinges on Canada's resource-heavy economy navigating tariffs, with diversification benefits for U.S. investors. Risks include escalated trade war impacts on Canadian exports and market volatility.
Trailing returns across standard periods
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →EWC is a country-specific ETF that tracks the performance of the Canadian equity market. It provides exposure to large and mid-sized companies in Canada, with heavy concentrations in financials and energy, including Royal Bank of Canada, Shopify, and Enbridge.
Read more on EWC →